Change in Preferred Hepatitis C Agent for Blue Cross Community CentennialSM Members, Effective March 1, 2019

March 11, 2019

Effective March 1, 2019, Blue Cross and Blue Shield of New Mexico (BCBSNM) updated its Blue Cross Community Centennial pharmacy formulary to include sofosbuvir/velpatasvir (the authorized generic of EPCLUSA®) as the preferred exclusive agent for hepatitis C products for Blue Cross Community Centennial members. When choosing sofosbuvir/velpatasvir for their patients who are Blue Cross Community Centennial members, providers should write prescriptions for “sofosbuvir/velpatasvir,” or specifically mark that the generic is requested. The prescription will not automatically be switched for the generic if only the brand name is written in the prescription.

Blue Cross Community Centennial members currently using other combination hepatitis C products may continue their current hepatitis C medication regimen with no changes at this time; this update will therefore not disrupt their current hepatitis C pharmacotherapy.

For questions regarding coverage, please refer Blue Cross Community Centennial members to the Member Services phone number on the back of their insurance ID card.

Such services are funded in part with the State of New Mexico.

EPCLUSA is the trademark of Gilead Sciences, Inc., or its related companies.

Prime Therapeutics, LLC is a separate company that serves as the Pharmacy Benefit Manager for Blue Cross Community Centennial.

Nothing in this communication is a substitute for the independent medical judgment of a health care provider. Providers must use their own best medical judgment based upon all available information and the patient’s condition in determining a course of treatment. Regardless of any benefit determination, the final decision regarding any treatment or service is between the patient and the provider.